Avascular Necrosis (Osteonecrosis) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Avascular Necrosis (Osteonecrosis) Market Outlook
Thelansis’s “Avascular Necrosis
(Osteonecrosis) Market Outlook, Epidemiology, Competitive Landscape, and Market
Forecast Report – 2024 To 2034" covers disease overview, epidemiology,
drug utilization, prescription share analysis, competitive landscape, clinical
practice, regulatory landscape, patient share, market uptake, market forecast,
and key market insights under the potential Avascular Necrosis (Osteonecrosis)
treatment modalities options for eight major markets (USA, Germany, France,
Italy, Spain, UK, Japan, and China).
Avascular
Necrosis (Osteonecrosis) Overview
Avascular
necrosis (AVN) of the femoral head is caused by the interruption of blood
supply to the bone of the proximal femur. The loss of blood supply can result
from both traumatic and non-traumatic causes and leads to cell death
(osteonecrosis). Significant necrosis leads to the total collapse of the
overlying articular cartilage of the femoral head secondary to the underlying
necrotic subchondral bone failure. This occurs before revascularization and
regeneration of the necrotic bone can occur due to loss of the underlying
structural rigidity of the affected bone as osteoclasts resorb it. The end
result of this process is early osteoarthritis (OA) of the hip. The patient
will often require a total hip replacement as the osteoarthritis progresses.
AVN occurs in 15% to 50% of cases of femoral neck and head fractures and 10% to
25% of hip dislocations. Internal fixation is generally preferred in young
patients to save the natural femoral head after a fracture. In contrast, in
older patients and elderly patients, primary arthroplasty may be performed to
restore mobility.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment